ClinicalTrials.gg
RecruitingNCT05043207Updated Nov 15, 2023

A Study Protocol for the Validation of UAud in a Clinical Setting.

An interventional study of uAud and Traditional audiometry in Hearing Loss, Sensorineural and Hearing Impairment, Sensorineural, sponsored by University of Southern Denmark. Recruiting at 1 site in Denmark. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-15.

Sponsored by University of Southern Denmark · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2022; still recruiting 4 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Hearing Loss, Sensorineural with a site in Denmark — 5 open to participants now, 6 under way, none of them phase 3. Hearing Loss, Sensorineural · Denmark.

Started
2022
with 2 others
No phase
5 of 10
2 open now
Registered
5th of 10
by date
Lead sponsor
2 of 10
University of Southern Denmark

Among the 10 studies in Hearing Loss, Sensorineural with a site in Denmark, this one is one of 3 that started in 2022, is one of 5 with no phase, and was the 5th registered.

Hearing Loss, Sensorineural

348 studies on the registry are indexed under Hearing Loss, Sensorineural; 103 are open to participants now.

Browse Hearing Loss, Sensorineural studies →

Open to participants now

5 of the 10 studies in Hearing Loss, Sensorineural with a site in Denmark are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 70 Hearing Loss, Sensorineural studies recruiting now, 39 (56%) set no upper age limit and 19 (27%) stop at 75 or younger; 26 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Hearing Loss, Sensorineural with a site in Denmark, or all of them as a file.
02

Study summary

The objective of this study is to validate the User-operated Audiometry (UAud) system for user-operated audiometry in a clinical setting, by investigating if hearing rehabilitation based on UAud is non-inferior to hearing rehabilitation based on traditional audiometry, and whether thresholds obtained with the user-operated version of the Audible Contrast Threshold (ACT) test correlates to traditional measures of speech intelligibility.

Read the detailed description

The project will focus on the initial examination of patients who are referred for hearing aid treatment. This initial examination consists of an audiometry which is currently conducted manually by an audiologist. However, it is possible to conduct an audiometry as a user-operated self-test by using a computer. The project will test if hearing rehabilitation based on the user-operated audiometry is non-inferior to hearing rehabilitation based on the gold standard of manual audiometry. The project will use several types of patient reported measures as well as objective measurements in the clinic. Research of this type is needed to understand if the quality of the hearing aid treatment is equal no matter the type of examination.

Also, the study will investigate whether thresholds obtained with the user-operated version of the Audible Contrast Threshold (ACT) test correlates to traditional measures of speech intelligibility.

03

Conditions studied

  • Hearing Loss, Sensorineural
  • Hearing Impairment, Sensorineural
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Sensorineural hearing loss with hearing thresholds exceeding 20 dB HL at two or more frequencies in the frequency range of 0.5 to 4 kHz.
  • Symmetric hearing loss with a maximum pure-tone average (PTA) (mean of 0.5-1-2-4 kHz) difference between the ears of 15 dB HL.
  • Danish native speaker.
  • No previous experience with HAs.
  • Capable of answering questionnaires through an online mailbox.

Exclusion criteria

Exclusion criteria

  • Air-conduction audiometry thresholds exceeding 80 dB HL at two or more frequencies.
  • Treatment affected by conductive hearing loss (air-bone gap >10 dB on more than one frequency below 1 kHz).
  • Conditions with fluctuating hearing loss, e.g., Menière's, on-going treatment with ototoxic drugs.
  • Ear, nose, or throat surgery in the past 12 months.
  • Evidence that the participant has made minor use of the HAs during the study (e.g., \< 2h per day).
  • Visual or motor impairment that might affect the use of the UAud system.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    uAud

    Patients which hearing aid is fitted based on the audiometry obtained with user-operated automated audiometry.

    Diagnostic Test: uAud

  • Active comparator
    control

    Patients which hearing aid is fitted based on the audiometry obtained with traditional audiometry.

    Diagnostic Test: Traditional audiometry

Interventions

  • Diagnostic testuAud

    Patients will receive hearing aid treatment based on an audiometry obtained with an user-operated automated audiometry procedure

  • Diagnostic testTraditional audiometry

    Patients will receive hearing aid treatment based on an audiometry obtained with an traditional audiometry procedure

06

What researchers measure

Primary outcomes

  1. SSQ12 (Speech, Spatial & Qualities of Hearing scale)

    A questionnaire reflecting the patient's subjective assessment of hearing in everyday life.

    Time frame: 3 months

Secondary outcomes

  1. HINT (Hearing In Noise Test)

    A performance test of patients speech intelligibility in noise.

    Time frame: 3 months

Other outcomes

  1. IOI-HA (International Outcome Inventory for Hearing Aids)

    A questionnaire regarding the patient's own perception of hearing aid outcome.

    Time frame: 3 months

  2. APHAB (Abbreviated Profile of Hearing Aid Benefit).

    A questionnaire regarding the patient's own perception of hearing and hearing aid outcome.

    Time frame: 3 months

  3. HINT-U (Hearing In Noise test - under amplification)

    A variation of the HINT framework targeting potential under amplification of hearing aid sound level.

    Time frame: 3 months.

  4. HINT-O (Hearing In Noise Test - Over amplification)

    A variation of the HINT framework targeting potential over amplification of hearing aid sound level.

    Time frame: 3 months.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Data is governed by the hospital's GPDR (General Data Protection Regulation) agreements.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in Sep 2023, 12 months.

Of 82 non-industry interventional studies with no phase under Hearing Loss, Sensorineural, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 83. This study's 12 months is below that.

Counting every sponsor, half of 162 studies reached it within 22 months; a quarter within 6 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2021
First posted
Sep 14, 2021
StartActual
Sep 1, 2022
Primary completionActual
Sep 1, 2023
CompletionEst.
Dec 1, 2024
Last update
Nov 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05043207
Collaborators
Innovation Fund Denmark, William Demant Fonden
Responsible party
Sponsor
First posted
Sep 14, 2021
Start date
Sep 1, 2022
Primary completion
Sep 1, 2023
Completion
Dec 1, 2024 (estimated)
Last update
Nov 15, 2023

Study contacts

Carl Pedersen, master's degree
Contact
pede@sdu.dk
+4531314965
Jesper Hvass Schmidt, PhD
principal investigator · SDU

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion